7 results on '"Utkan G"'
Search Results
2. Primary extranodal non-Hodgkin's lymphoma presenting as painful gingival swelling.
- Author
-
Ürün Y, Can F, Bariş E, Akbulut H, Utkan G, and İçli F
- Subjects
- Diagnosis, Differential, Gingival Neoplasms therapy, Humans, Lymphoma, Large B-Cell, Diffuse therapy, Male, Middle Aged, Treatment Outcome, Gingival Hypertrophy pathology, Gingival Neoplasms pathology, Lymphoma, Large B-Cell, Diffuse pathology
- Abstract
Primary extra-nodal non-Hodgkin's lymphomas (NHL) constitute 25-40% of NHL but less than 1% arises in oral cavity. Here in 53-year-old man with stage IE gingival diffuse large B cell lymphoma who was treated successfully with chemotherapy and radiotherapy was presented.
- Published
- 2012
3. Kikuchi--Fujimoto disease: cervical lymphadenopathy suggestive of relapsing lymphoma in patient with lymphoblastic lymphoma.
- Author
-
Urun Y, Utkan G, Kankaya D, Dogan M, Yalcin B, and İcli F
- Subjects
- Adult, Diagnosis, Differential, Humans, Lymph Nodes pathology, Male, Neck, Recurrence, Histiocytic Necrotizing Lymphadenitis diagnosis, Precursor Cell Lymphoblastic Leukemia-Lymphoma diagnosis
- Abstract
Aim: Kikuchi - Fujimoto disease (KFD) or histiocytic necrotizing lymphadenitis is a rare disorder and often confused with lymphoma., Patient: There is presented a case of 28-year-old patient with cervical lymphadenopathy, who had history of lymphoma., Results: On immunohistopathologic examination diagnosis of KFD was made and patient followed without any treatment., Conclusion: Patient's lymphadenopathy had almost resolved and he was completely asymptomatic after three months. In patient with cervical lymphadenopathy KFD should be considered in the differential diagnosis.
- Published
- 2011
4. Two cases with atypical metastasis in colorectal cancer: splenic and renal metastasis.
- Author
-
Dogan M, Ozal G, Ekinci C, Utkan G, Urun Y, Yalcin B, and Icli F
- Subjects
- Adenocarcinoma therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms therapy, Combined Modality Therapy, Digestive System Surgical Procedures, Humans, Kidney Neoplasms therapy, Lung Neoplasms secondary, Lung Neoplasms therapy, Male, Middle Aged, Palliative Care, Splenic Neoplasms therapy, Adenocarcinoma pathology, Colorectal Neoplasms pathology, Kidney Neoplasms secondary, Splenic Neoplasms secondary
- Abstract
Unlabelled: Atypical metastasis, such as splenic and renal metastasis is rare in colorectal cancer. There have been case reports of colorectal cancer patients with isolated splenic metastasis, even after years of surgery in the literature., Aim: To report two colorectal cancer cases with atypical metastasis., Results: The first patient was a 58-year old man who had isolated splenic metastasis after 20 months of surgery. The other one was a 51-year old male patient with both lung and renal metastasis at rectal cancer diagnosis. Splenic and renal metastases have been histopathologically documented in both of them. The first patient was given chemotherapy after splenectomy. The other one had also multiple lung metastases besides renal metastasis. He received palliative chemotherapy.
- Published
- 2010
5. Blood viscosity in patients with diffuse large B cell non-Hodgkin's lymphoma.
- Author
-
Utkan G, Tek I, Kocer M, Muallaoglu S, Durnal AG, Arslan UY, Celenkoglu G, Tokluoglu S, and Alkis N
- Subjects
- Adult, Aged, Female, Humans, Lymphoma, B-Cell pathology, Lymphoma, Large B-Cell, Diffuse pathology, Male, Middle Aged, Blood Viscosity, Lymphoma, B-Cell blood, Lymphoma, Large B-Cell, Diffuse blood
- Abstract
Unlabelled: The aim of the study was to evaluate blood viscosity as possible marker of disease progression in patients with newly diagnosed non-Hodgkin's lymphoma (NHL)., Methods: The viscosity of blood samples from 20 patients with newly diagnosed aggressive NHL (stage I, n=7; stage II, n=4; stage III, n=7; stage IV, n=2) was analyzed using Brookfield DV-II + (USA) machine., Results: Blood viscosity in NHL patients (median: 5.5+/-1.46 miliPascal) inversely correlated with lactatdehydrogenase (LDH) level, international prognostic index (IPI) score, and stage (p=0.02, r=-0.51; p=0.03, r=-0.63; and p=0.04, r=-0.45, respectively) and positively correlated with hemoglobin level (p=0.02, r=0.65))., Conclusion: According to our data, blood viscosity may be considered as a follow up marker in NHL patients along with LDH level or sedimentation rate.
- Published
- 2006
6. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
- Author
-
Yalcin B, Pamir A, Buyukcelik A, Utkan G, Akbulut H, Demirkazik A, and Icli F
- Subjects
- Adolescent, Adult, Antineoplastic Agents, Alkylating administration & dosage, Antineoplastic Agents, Alkylating adverse effects, Bone Neoplasms pathology, Bone Neoplasms surgery, Child, Disease-Free Survival, Dose-Response Relationship, Drug, Female, Granulocyte Colony-Stimulating Factor administration & dosage, Granulocyte-Macrophage Colony-Stimulating Factor administration & dosage, Humans, Ifosfamide administration & dosage, Ifosfamide adverse effects, Infusions, Intravenous, Male, Mesna administration & dosage, Middle Aged, Sarcoma pathology, Sarcoma surgery, Treatment Outcome, Antineoplastic Agents, Alkylating therapeutic use, Bone Neoplasms drug therapy, Ifosfamide therapeutic use, Sarcoma drug therapy
- Abstract
Aim: Ifosfamide and doxorubicin are the most effective agents in the treatment of sarcomas, although their contributions to survival are usually limited. High-dose ifosfamide can be used as a salvage treatment in patients with recurrent or advanced sarcoma. We evaluated efficacy and toxicity of high-dose ifosfamide in the patients with recurrent or advanced sarcoma in this study., Methods: 39 patients with recurrent or advanced sarcoma were enrolled onto the study between 1996 and 2002. All patients had histological proven high grade sarcoma with measurable or evaluable disease. Ifosfamide was administered at the dose of 2 g/m(2) as continuous intravenous infusion for 24 h on day 1-9, in conjunction with the continuous infusion of mesna. Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor was given every cycle. The efficacy and toxicity of high dose ifosfamide (HDI) were evaluated clinically before subsequent cycle. The objective response was evaluated every two cycles. Histopathologic response was also evaluated in patients who underwent surgical resection., Results: Male/female ratio was 24/15, with a median age of 20 (11-48) years. 9 patients had locally inoperable advanced disease and 30 patients had metastatic disease. 10 patients were chemo-naive. The total number of HDI-chemotherapy cycles was 103 (median 2 cycles (range, 1 to 7)). 2 patients refused the further treatment after the first cycle and 1 patient died due to neutropenic sepsis in the first cycle of treatment. 36 patients were available for the evaluation of treatment efficacy. Overall response rates were 53.8% and 90% in pre-treated patients and in chemo-naive patients, respectively. Median follow-up time was 43 months. 13 patients underwent total surgical tumor resection. Pathologic complete response was observed in 5 of 13 these patients who underwent surgery. Median progression-free survival (PFS) was 7 months (95%CI: 3.8-10.2). The median progression-free survival (PFS) were 3 and 12 months in patients who did not have tumor resection, and in those having complete tumor resection (p = 0.002). Median overall survival (OS) was 10 months (95%CI: 0.0-20) in all patients. Median OS times were 8 months in patients without tumor resection and 26.5 months in patients with those underwent surgical treatment (p = 0.0369). 2 patients who underwent surgery are still alive and disease-free. Major toxicity was myelosuppression., Conclusion: HDI seems to be feasible and effective in selected patients with advanced or recurrent sarcomas. Survival advantage of HDI is better when the total tumor resection can be done.
- Published
- 2004
7. Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma.
- Author
-
Akbulut H, Icli F, Yalcin B, Demirkazik A, Onur H, Buyukcelik A, and Utkan G
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bone Neoplasms drug therapy, Bone Neoplasms secondary, Camptothecin administration & dosage, Cisplatin administration & dosage, Colorectal Neoplasms pathology, Dacarbazine administration & dosage, Disease-Free Survival, Female, Humans, Irinotecan, Liver Neoplasms drug therapy, Liver Neoplasms secondary, Lung Neoplasms drug therapy, Lung Neoplasms secondary, Male, Middle Aged, Survival Rate, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Camptothecin analogs & derivatives, Colorectal Neoplasms drug therapy
- Abstract
Aim: Irinotecan is an active drug after fluorouracil (FU) failure in patients with colorectal cancer (CRC). Also a modest activity of cisplatin and dacarbazine combination in FU resistant patients have been reported. We aimed to assess the efficacy of irinotecan, cisplatin and dacarbazine combination in previously treated patients with measurable advanced CRC., Methods: Treatment schedule was irinotecan 150 mg/m2, iv, d1; cisplatin 20 mg/m2 and dacarbazine 200 mg/m2 iv, d1-d3; every 21 days. 48 patients with a median age of 51 were entered the study., Results: Objective response rate was 33.3%. The overall disease stabilization rate was 75.6%. The median survival was 14 months, and the median progression-free survival was 7 months. Main toxicities were grade 2-3 vomiting (39.2%) and grade 3-4 neutropenia (17.4%)., Conclusion: CPD combination seems to be very active, with acceptable safety profile, in patients with advanced CRC resistant to FUFA.
- Published
- 2004
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.